{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T09:05:31Z","timestamp":1764493531680},"reference-count":51,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Revista Cl\u00ednica Espa\u00f1ola"],"published-print":{"date-parts":[[2005,3]]},"DOI":"10.1157\/13072971","type":"journal-article","created":{"date-parts":[[2005,4,6]],"date-time":"2005-04-06T14:29:49Z","timestamp":1112797789000},"page":"127-136","source":"Crossref","is-referenced-by-count":5,"title":["Aplicaciones de anticuerpos monoclonales y productos de biotecnolog\u00eda en el tratamiento de las enfermedades inflamatorias cr\u00f3nicas"],"prefix":"10.1016","volume":"205","author":[{"given":"J.L.","family":"Marenco de la Fuente","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1157\/13072971_bib1","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/art.1780301102","article-title":"The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis","volume":"30","author":"Gregersen","year":"1987","journal-title":"Arthritis Rheum"},{"key":"10.1157\/13072971_bib2","doi-asserted-by":"crossref","first-page":"908","DOI":"10.7326\/0003-4819-136-12-200206180-00012","article-title":"Rheumatoid arthritis-A molecular understanding","volume":"136","author":"Bruce Smith","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1157\/13072971_bib3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0889-857X(03)00115-7","article-title":"Cytokines in the rheumatic diseases","volume":"30","author":"Arend","year":"2004","journal-title":"Rheum Dis Clin N Am"},{"key":"10.1157\/13072971_bib4","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0092-8674(00)81109-5","article-title":"Rheumatoid arthritis","volume":"85","author":"Feldmann","year":"1996","journal-title":"Cell"},{"key":"10.1157\/13072971_bib5","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","article-title":"Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis","volume":"41","author":"Maini","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1157\/13072971_bib6","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.rdc.2004.01.009","article-title":"Infliximab treatment of rheumatoid arthritis","volume":"30","author":"Maini","year":"2004","journal-title":"Rheum Dis Clin N Am"},{"key":"10.1157\/13072971_bib7","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis","volume":"343","author":"Lipsky","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1157\/13072971_bib8","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1080\/030097402317255372","article-title":"Pulmonary miliary tuberculosis in a patient with anti-TNF-alpha treatment","volume":"31","author":"Mayordomo","year":"2002","journal-title":"Scand J Rheumatol"},{"key":"10.1157\/13072971_bib9","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1157\/13072971_bib10","first-page":"49","article-title":"Las terapias biol\u00f3gicas y las infecciones","volume":"1","author":"Marenco","year":"2003","journal-title":"Rev Esp Reumatol"},{"key":"10.1157\/13072971_bib11","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1002\/art.11137","article-title":"Treatment of rheumatoid arthritis with tumor necrosis factor inhibitor may predispose to significant increase in tuberculosis risk: a multicenter active surveillance report","volume":"48","author":"G\u00f3mez-Reino","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1157\/13072971_bib12","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W","article-title":"Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides","volume":"44","author":"Mohan","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1157\/13072971_bib13","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1002\/art.10679","article-title":"Tumor necrosis factor against therapy and lymphoma development","volume":"46","author":"Brown","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1157\/13072971_bib14","first-page":"241","article-title":"The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes","volume":"30","author":"Chakravarty","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1157\/13072971_bib15","doi-asserted-by":"crossref","first-page":"807","DOI":"10.7326\/0003-4819-138-10-200305200-00008","article-title":"Case reports of heart failure after therapy with a tumor necrosis factor antagonist","volume":"138","author":"Kwon","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1157\/13072971_bib16","unstructured":"Suhler E, Smith JR, Lauer AK, Kurtz DE, Wertheim MS, Pickard TD, et al. A prospective trial of infliximab therapy for patients with refractory uveitis: interim analysis of safety and efficacy outcomes. Association for Research in Vision and Ophthalmology Annual Meeting 2004. [Internet. Cited April 15, 2004]. Abstract and Program Planner 2003. Disponible en http:\/\/www.arvo.org."},{"key":"10.1157\/13072971_bib17","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1172\/JCI19284","article-title":"Antithrombotic activity of TNF-alpha","volume":"112","author":"Cambien","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1157\/13072971_bib18","first-page":"1241","article-title":"Blind insight: eyeing anti-tumor necrosis factor treatment in uveitis associated with Beh\u00e7et disease","volume":"31","author":"Rosenbaum","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1157\/13072971_bib19","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/S0140-6736(01)06677-6","article-title":"Effect of Infliximab on threatening panuveit is in Beh\u00e7et disease [carta]","volume":"358","author":"Mu\u00f1oz-Fern\u00e1ndez","year":"2001","journal-title":"Lancet"},{"key":"10.1157\/13072971_bib20","doi-asserted-by":"crossref","first-page":"404","DOI":"10.7326\/0003-4819-140-5-200403020-00025","article-title":"Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Beh\u00e7et disease [carta]","volume":"140","author":"Sfikakis","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1157\/13072971_bib21","first-page":"1362","article-title":"Efficacy, safety and pharmacokinetics of multiple administration of infliximab in Beh\u00e7et's disease with refractory uveoretinitis","volume":"31","author":"Ohno","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1157\/13072971_bib22","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ophtha.2003.10.012","article-title":"Infliximab treatment of posterior uveitis [carta]","volume":"111","author":"Mansour","year":"2004","journal-title":"Ophthalmology"},{"issue":"Suppl","key":"10.1157\/13072971_bib23","first-page":"S181","article-title":"The response of treatment resistant uveitis in Beh\u00e7et's syndrome (BS) to a TNF-alpha blocker, etanercept: an open study [abstract]","volume":"46","author":"Melikoglu","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1157\/13072971_bib24","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0950-3579(05)80305-X","article-title":"The epidemiology of drug treatment failure in rheumatoid arthritis","volume":"9","author":"Wolfe","year":"1995","journal-title":"Baillieres Clin Rheumatol"},{"key":"10.1157\/13072971_bib25","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.rdc.2004.02.004","article-title":"Adalimumab therapy in rheumatoid arthritis","volume":"30","author":"Keystone","year":"2004","journal-title":"Rheum Dis Clin N Am"},{"key":"10.1157\/13072971_bib26","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/rheumatology\/34.4.334","article-title":"The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis","volume":"34","author":"Rankin","year":"1995","journal-title":"Br J Rheumatol"},{"key":"10.1157\/13072971_bib27","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/rheumatology\/41.10.1133","article-title":"Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial","volume":"41","author":"Choy","year":"2002","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl 1","key":"10.1157\/13072971_bib28","article-title":"Onceweekly administration of 50 mg etanercept (enbrel) results of a phase III multicenter clinical trial","volume":"62","author":"Keystone","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1157\/13072971_bib29","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1093\/rheumatology\/keg135","article-title":"Dose reduction of etanercept-can we treat more patients using a fixed budget?","volume":"42","author":"Clunie","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"10.1157\/13072971_bib30","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1056\/NEJM199901283400401","article-title":"A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate","volume":"340","author":"Weinblatt","year":"1999","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"10.1157\/13072971_bib31","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/ar1013","article-title":"Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis?","volume":"6","author":"Schwartzman","year":"2004","journal-title":"Arthritis Res Ther"},{"key":"10.1157\/13072971_bib32","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1002\/art.10308","article-title":"Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes","volume":"46","author":"Genovese","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1157\/13072971_bib33","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(04)15640-7","article-title":"Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial","volume":"363","author":"Klareskog","year":"2004","journal-title":"Lancet"},{"key":"10.1157\/13072971_bib34","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/ard.62.1.74","article-title":"Efficacy of etanercept for treatment of Crohn's related spondyloarthritis but not colitis","volume":"62","author":"Marzo-Ortega","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1157\/13072971_bib35","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.rdc.2004.01.004","article-title":"Treatment of rheumatoid arthritis with etanercept","volume":"30","author":"Genovese","year":"2004","journal-title":"Rheum Dis Clin N Am"},{"key":"10.1157\/13072971_bib36","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1086\/383317","article-title":"Granulomatous infectious diseases associated with tumor necrosis factor antagonists","volume":"38","author":"Wallis","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13072971_bib37","first-page":"1356","article-title":"Pneumococcal vaccine responses in psoriatic arthritis patients during treatment with etanercept","volume":"31","author":"Mease","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1157\/13072971_bib38","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/art.20311","article-title":"Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients","volume":"50","author":"Wolfe","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1157\/13072971_bib39","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1046\/j.1365-2036.2003.01414.x","article-title":"Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study","volume":"17","author":"Rutgeerts","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1157\/13072971_bib40","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1002\/art.20303","article-title":"Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial","volume":"50","author":"Nishimoto","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1157\/13072971_bib41","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1053\/j.gastro.2004.01.012","article-title":"A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease","volume":"126","author":"Ito","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1157\/13072971_bib42","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.rdc.2004.01.005","article-title":"The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis","volume":"30","author":"Cohen","year":"2004","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1157\/13072971_bib43","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1002\/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO;2-2","article-title":"Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist","volume":"41","author":"Bresnihan","year":"1998","journal-title":"Arthritis Rheum"},{"issue":"Suppl 1","key":"10.1157\/13072971_bib44","first-page":"186","article-title":"An evaluation of the use of anakinra by rheumatoid arthritis patients previously treated with a TNF inhibitor","volume":"62","author":"Zif","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1157\/13072971_bib45","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.rdc.2004.02.002","article-title":"Cytotoxic T-lymphocyte antigen 4-immunoglobulin in rheumatoid arthritis","volume":"30","author":"Kremer","year":"2004","journal-title":"Rheum Dis Clin N Am"},{"key":"10.1157\/13072971_bib46","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1157\/13072971_bib47","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.rdc.2004.01.006","article-title":"B-lymphocyte depletion therapy with rituximab in rheumatoid arthritis","volume":"30","author":"Edwards","year":"2004","journal-title":"Rheum Dis Clin N Am"},{"key":"10.1157\/13072971_bib48","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.2174\/1381612033454991","article-title":"Anti-cytokines and cytokines in the treatment of rheumatoid arthritis","volume":"9","author":"Taylor","year":"2003","journal-title":"Curr Pharm Des"},{"key":"10.1157\/13072971_bib49","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1186\/ar309","article-title":"Results of a phase-I\/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis","volume":"3","author":"Moreland","year":"2001","journal-title":"Arthritis Res"},{"key":"10.1157\/13072971_bib50","unstructured":"Lim WC, Hanauer SB. Emerging biologic therapies in inflammatory bowel disease reviews in gastroenterological disorders. 2004; 4:61-85."},{"key":"10.1157\/13072971_bib51","first-page":"1021","article-title":"Is there a rationale for switching from one anti-tumor necrosis factor agent to another?","volume":"31","author":"Haraoui","year":"2004","journal-title":"J Rheumatol"}],"container-title":["Revista Cl\u00ednica Espa\u00f1ola"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014256505725078?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014256505725078?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,27]],"date-time":"2019-01-27T18:27:04Z","timestamp":1548613624000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014256505725078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["S0014256505725078"],"URL":"https:\/\/doi.org\/10.1157\/13072971","relation":{},"ISSN":["0014-2565"],"issn-type":[{"value":"0014-2565","type":"print"}],"subject":[],"published":{"date-parts":[[2005,3]]}}}